Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2019 March;85(3) > Minerva Anestesiologica 2019 March;85(3):271-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

Minerva Anestesiologica 2019 March;85(3):271-8

DOI: 10.23736/S0375-9393.18.12326-1

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Investigating propofol-sufentanil interaction using clinical endpoints and processed electroencephalography: a prospective randomized controlled trial

Frank WEBER 1 , Christopher PRASSER 2

1 Pediatric Anesthesia Unit, Department of Anesthesiology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; 2 Department of Anesthesiology, University Hospital Regensburg, Regensburg, Germany



BACKGROUND: Propofol and sufentanil target controlled infusion technology is used with increasing frequency. Drug interaction modelling, using clinical endpoints and processed electroencephalography helps determine optimal drug concentrations to assure adequate anesthesia.
METHODS: Sixty patients were randomized to receive a constant concentration of sufentanil (0.25 ng/mL (Group S0.25), 0.5 ng/mL (Group S0.5), 0 ng/mL (Group S0). Propofol was administered in steps of 0.5 µg/mL, up to 4 µg/mL. Processed EEG (Bispectral Index, Narcotrend Index) and auditory evoked potentials (composite A-Line autoregressive Index; cAAI), were recorded simultaneously. Sufentanil-propofol interaction was assessed by Probit - and nonlinear regression analysis.
RESULTS: Sufentanil had a dose-dependent synergistic effect on the effect-site concentration of propofol (µg/mL) associated with a 50% probability (EC50) of loss of responsiveness to verbal command (S0: 2.84 µg/mL, R2 0.773; S0.25: 1.95 µg/mL, R2 0.862; S0.5: 1.48 µg/mL, R2 0.887) and noxious stimulation (S0: 3.46 µg/mL, R2 0.626 µg/mL; S0.25: 2.17 µg/mL, R2 0.853; S0.5: 1.69 µg/mL, R2 0.897). Non-linear regression analysis revealed a synergistic sufentanil effect on the propofol EC50 for BIS (S0: 3.36 µg/mL, R2 0.79; S0.25: 2.77 µg/mL, R2 0.86 µg/mL; S0.5: 2.6 µg/mL, R2 0.84), Narcotrend Index (S0: 3.57 µg/mL, R2 0.66; S0.25: 2.91 µg/mL, R2 0.70; S0.5: 2.02 µg/mL, R2 0.51) and cAAI (S0: 3.42 µg/mL, R2 0.59; S0.25: 3.00 µg/mL, R2 0.63; S0.5: 3.14 µg/mL, R2 0.59).
CONCLUSIONS: Sufentanil has a synergistic effect on the clinically observed hypnotic properties of propofol. These findings apply also to the depth of hypnosis measured by the Bispectral Index, Narcotrend Index and cAAI.


KEY WORDS: Propofol - Sufentanil - Drug interactions - Electroencephalography

top of page